Anavex announces issuance of new u.s. intellectual property compositions patent for anavex®2-73 (blarcamesine)

New york, june 01, 2023 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including alzheimer's disease, parkinson's disease, rett syndrome and other central nervous system (cns) disorders, announced today it was awarded new u.s. patent no. 11,661,405 entitled “crystal forms of tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, processes of making such forms, and their pharmaceutical compositions” from the united states patent and trademark office (uspto), expanding anavex's patent coverage of certain crystal forms of anavex®2-73 (blarcamesine) compositions, processes of preparation, and uses thereof.
AVXL Ratings Summary
AVXL Quant Ranking